Insider Transactions in Q2 2023 at Zentalis Pharmaceuticals, Inc. (ZNTL)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2023
|
Matrix Capital Management Company, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,760,000
+25.43%
|
$104,720,000
$22.66 P/Share
|
|
Jun 16
2023
|
Jan Skvarka Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,364
+23.6%
|
-
|
|
Jun 16
2023
|
Enoch Kariuki Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,364
+30.0%
|
-
|
|
Jun 16
2023
|
David Michael Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,059
+13.01%
|
-
|
|
May 31
2023
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
27,768
-2.86%
|
$721,968
$26.3 P/Share
|
|
May 26
2023
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
80,000
-84.21%
|
$2,400,000
$30.02 P/Share
|
|
May 08
2023
|
Diana Hausman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,732
+50.0%
|
-
|